Palisade Bio (NASDAQ:PALI) Director Buys $19,800.00 in Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were purchased at an average price of $1.98 per share, with a total value of $19,800.00. Following the completion of the transaction, the director owned 366,904 shares of the company’s stock, valued at $726,469.92. The trade was a 2.80% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Robert Jr. Baltera also recently made the following trade(s):

• On Tuesday, July 7th, Robert Jr. Baltera bought 30,000 shares of Palisade Bio stock. The stock was purchased at an average price of $2.03 per share, for a total transaction of $60,900.00.
• On Monday, July 6th, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was purchased at an average cost of $2.05 per share, with a total value of $41,000.00.
• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The shares were purchased at an average price of $1.98 per share, with a total value of $39,600.00.

Palisade Bio Stock Performance

PALI stock opened at $2.05 on Thursday. The firm has a market cap of $355.84 million, a PE ratio of -2.03 and a beta of 1.50. The firm’s 50 day moving average price is $1.92 and its 200-day moving average price is $1.92. Palisade Bio, Inc. has a one year low of $0.53 and a one year high of $2.86.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Equities research analysts predict that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.

Palisade Bio News Summary

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: Director Robert Jr. Baltera bought 30,000 shares at about $2.03 per share, following earlier purchases of 20,000 shares and 10,000 shares at $1.98. Repeated insider buying can signal confidence in Palisade Bio’s outlook. SEC filing
• Positive Sentiment: Analysts remain broadly constructive on Palisade Bio, with recent ratings including a “strong-buy” upgrade and multiple buy ratings, plus a consensus price target well above the current trading range. MarketBeat PALI page
• Neutral Sentiment: CEO John David Finley sold 146,798 shares, but the filing says the transaction was to cover tax withholding obligations tied to vesting equity awards, which makes the sale less concerning than a discretionary insider exit. SEC filing
• Neutral Sentiment: Insider Mitchell Lawrence Jones also sold shares for the same tax-withholding reason, adding to the day’s mixed insider activity. SEC filing

Hedge Funds Weigh In On Palisade Bio

Several hedge funds have recently bought and sold shares of PALI. Cetera Investment Advisers purchased a new position in Palisade Bio during the 4th quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in Palisade Bio during the fourth quarter worth about $26,000. Virtu Financial LLC acquired a new stake in shares of Palisade Bio during the fourth quarter worth about $28,000. CTC Alternative Strategies Ltd. acquired a new stake in shares of Palisade Bio during the first quarter worth about $31,000. Finally, Atom Investors LP purchased a new position in shares of Palisade Bio in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on PALI shares. Oppenheimer set a $7.00 target price on shares of Palisade Bio in a research report on Tuesday, June 30th. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a report on Tuesday, June 30th. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Finally, Wolfe Research assumed coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Palisade Bio presently has an average rating of “Buy” and an average price target of $8.83.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.